Skip to Content
Søk Menu

SABCS2020: Trastuzumab Deruxtecan Continues to Demonstrate Durable Responses in HER2 Positive Metastatic Breast Cancer

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Related

Consecutive Mammography Screening Is the Best Way to Reduce the Risk of Premature Death from Breast Cancer

/ Sofie Pohl
Brystkreft

Recent Updates in Breast Cancer Screening – A Norwegian Perspective

/ Kaitlyn Tsuruda / Solveig Hofvind
Brystkreft
László Tabár

Mammography Screening Is the Best Way to Reduce the Risk of a Premature Death from Breast Cancer

/ László Tabár
Brystkreft Play the Video 7:11

ASCO GI 2024: Targeting HER2 in Gastroesophageal Adenocarcinoma

/ Sofie Pohl
ASCOGI24BrystkreftGastrointestinal kreft
Hatem Azim

Using Fertility Options May be Safe for Patients with HR-positive Breast Cancer

/ Hatem Azim
BrystkreftSABCS23 Play the Video 10:10
Terry Mamounas

The Effectiveness of Regional Nodal Radiation in Patients with Breastcancer

/ Eleftherios (Terry) P. Mamounas
BrystkreftSABCS23 Play the Video 13:26

SABCS 2023: HR-Positive Breast Cancer Patients May Safely Use Fertility Options

/ BestPractice Nordic
BrystkreftSABCS23

SABCS 2023: Younger Postmenopausal Women May Safely Skip Adjuvant Radiotherapy

/ BestPractice Nordic
BrystkreftSABCS23

SABCS 2023: Neoadjuvant Chemotherapy: May Reduce Regional Nodal Irradiation in Breast Cancer Patients

/ BestPractice Nordic
BrystkreftSABCS23
Back to top